更新于：2024-05-01

Balkan Nephropathy

巴尔干肾病

更新于：2024-05-01

基本信息

别名

BALKAN ENDEMIC NEPHROPATHY、BEN、Balkan Endemic Nephropathy

+ [28]

简介

A form of chronic interstitial nephritis that is endemic to limited areas of BULGARIA, the former YUGOSLAVIA, and ROMANIA. It is characterized by a progressive shrinking of the KIDNEYS that is often associated with uroepithelial tumors.

关联

项与巴尔干肾病相关的药物

MAU-868

靶点

诺如病毒衣壳蛋白VP1

作用机制

诺如病毒衣壳蛋白VP1抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期1800-01-20

项与巴尔干肾病相关的临床试验

NCT04323904 / RecruitingN/AIIT

Hantavirus Registry - HantaReg

Hantavirus disease are zoonotic infections and remain a clinical challenge with globally increasing incidence and multiple serious outbreak situations in Europe within the last years. Hantavirus disease encompasses two clinical syndromes, hemorrhagic fever with renal syndrome (HFRS) and hantavirus cardiopulmonary syndrome (HCPS) caused by Old World and New World hantaviruses, respectively. Depending on the causative Old World hantavirus species, clinical course of HFRS can vary from mild to moderate to severe.
At present, there is no specific therapy available for hantavirus disease. As the clinical course of hantavirus disease is dependent on the causing viral pathogen and as there worrisome hints that clinical course HFRS and HCPS overlap, further studies with regard to the disease course are mandatory. Furthermore, the examination of attributable mortality and costs of hantavirus disease will need to be studied on a multinational basis and therefore HantaReg will particularly use a matched case control design.

开始日期2020-03-04

申办/合作机构

University of Cologne Executive School GmbH

NCT02404155 / CompletedN/AIIT

Biomarker and Safety Study of Clozapine in Patients With Benign Ethnic Neutropenia (BEN)

Clozapine (CLZ) is the most effective antipsychotic for treatment-refractory schizophrenia (SZ). Despite the overwhelming evidence of superior efficacy, CLZ is infrequently prescribed in the US, at a considerably lower rate than the estimated prevalence of treatment-resistant SZ, especially for African-Americans (AA). Recent evidence suggests that low Absolute Neutrophil Counts (ANC), either at baseline or during treatment are a significant barrier to CLZ use in AA patients in the US, where guidelines mandate CLZ discontinuation if ANC drops below 1500 cells/mm3. The investigators group has found that discontinuation of CLZ in AA patients is over twice that in European-American (EA) patients (N
400; 42% vs.19%, P=0.041) and initiation rates are 50% lower. In a Statewide study (N=1875), the investigators reported that discontinuation was more frequently due to neutropenia in the AA sample, though no AA had developed agranulocytosis (8 cases in EA). Benign Ethnic Neutropenia (BEN) in people of African ancestry, including AAs, identifies a group (50% of AA) with low ANCs but no increased risk of agranulocytosis or infection. Low baseline or in-treatment fluctuations requiring CLZ discontinuation under current prescribing guidelines are common in CLZ-treated persons with BEN. In the investigators recent pilot study of N=12 AA patients with BEN, treatment was safely and successfully continued with CLZ despite low baseline ANC (outside current guidelines). Recent evidence implicates a polymorphism in the Duffy Antigen Receptor Chemokine (DARC) gene in the pathophysiology of BEN. In homozygotes (FY-/-) for the DARC null allele, mean within-subject neutrophil counts are reduced, resulting in sporadic ANC <1500 cells/mm3 in 10-15% of people with the allele. In population studies, the FY-/- genotype is found in 0.01% of EAs, 99.3% of sub-Saharan Africans (SSA), and 68% of AAs. Further, a missense DARC mutation has been reported to interact with the DARC FY-/- in determining low WBC in AAs. Normal patterns of week-to-week fluctuation in ANC levels in individuals of African ancestry with BEN and the DARC null genotype are not known, and no published research has examined variation in ANC in African ancestry CLZ-treated SZ patients with BEN and the DARC null genotype (FY-/-). Such data are also lacking on individuals with BEN without the DARC null genotype. Conducting such research will generate genetic marker and safety data that could be used to expand access to CLZ for AA patients who otherwise are eligible to receive this superior treatment option.

开始日期2015-07-01

申办/合作机构

University of Maryland Baltimore

NCT02455375 / CompletedN/A

Puumala Hantavirus Infection in France: Evaluation of Commercial Assays for the Detection of Antibodies Against This Virus and the Use of Urine Samples for the Molecular Detection of This Infection

Routine Puumala virus (PUUV) infection diagnosis is performed using serological commercial kits of which performances have not been established in real life, which use recombinant protein from strains from Central or North Europe. Molecular diagnostic of these infection is not the rule. Consequently the objectives of the project are to evaluate the performances of the serological commercial assays in real life in France and to assess the use of urine versus plasma for the molecular diagnostic of this infection.

开始日期2015-07-01

申办/合作机构

Centre Hospitalier de Charleville-Mézières

[+1]

100 项与巴尔干肾病相关的临床结果

登录后查看更多信息

100 项与巴尔干肾病相关的转化医学

登录后查看更多信息

0 项与巴尔干肾病相关的专利（医药）

登录后查看更多信息

1,095

项与巴尔干肾病相关的文献（医药）

2024-02-17·Viruses

Rosuvastatin as a Supplemental Treatment for the Clinical Symptoms of Nephropathia Epidemica: A Pilot Clinical Study.

Article

作者: Venera Shakirova ; Maria Markelova ; Yuriy Davidyuk ; Robert J Stott-Marshall ; Toshana L Foster ; Svetlana Khaiboullina ; Albert Rizvanov ; Ekaterina Martynova

Nephropathis epidemica (NE), a mild form of hemorrhagic fever with renal syndrome (HFRS), is an acute zoonotic disease endemic in the Republic of Tatarstan. This study aimed to assess the impact of rosuvastatin on the clinical and laboratory results of NE. A total of 61 NE patients and 30 controls were included in this study; 22 NE patients and 7 controls received a daily dose of rosuvastatin (10 mg) for ten consecutive days. Serum samples were collected on days 1, 5, and 10 after admission to the hospital. These samples were analyzed to determine the levels of lipids, cytokines, and kidney toxicity markers. Our findings indicate that rosuvastatin reduced the duration of the second wave of fever and alleviated back pain and headache symptoms. Additionally, low-density lipoprotein cholesterol (LDL-C) serum levels were significantly decreased on days 5 and 10 upon rosuvastatin treatment. Furthermore, rosuvastatin decreased the levels of cytokines in the serum, particularly proinflammatory cytokines IL-1β and IL-8. NE patients had significantly altered levels of the kidney toxicity markers albumin and osteopontin. The data from our study provide evidence supporting the therapeutic potential of rosuvastatin in NE cases.

2024-01-22·Schizophrenia research

Safety of BEN guidelines in clozapine treatment: A Canadian perspective.

Article

作者: Sally Wu ; Valerie Powell ; Araba Chintoh ; Mohammed Alarabi ; Sri Mahavir Agarwal ; Gary Remington

OBJECTIVE:

Unidentified benign ethnic neutropenia (BEN) has been recognized as a factor contributing to clozapine underutilization and discontinuation. Guidelines were implemented to accommodate BEN in Canada, and our main objective was to evaluate clozapine's safety in a sample of Canadian psychiatric patients with BEN.

METHOD:

A retrospective chart review was conducted at the Centre for Addiction and Mental Health, Toronto, Canada. Through the clozapine clinic registry, participants were identified who (i) received clozapine using the approved BEN guidelines for hematological monitoring, and (ii) had at least one complete blood count pre- and post-clozapine initiation.

RESULTS:

Our sample population was comprised of 41 BEN patients who were African-Caribbean (49 %), African (34 %), African-North American (12 %), Middle Eastern (2 %), and Indian-Caribbean (2 %). There was a significant reduction in hematological alerts for these patients while monitored under BEN guidelines (p < 0.001). The mean within-patient ANC value was not significantly different one year after clozapine initiation compared to the pre-clozapine baseline (p = 0.069). None of the patients discontinued clozapine for hematological reasons.

CONCLUSIONS:

Findings demonstrated that patients monitored under the modified hematological guidelines for BEN can be safely treated with clozapine. These findings have important clinical ramifications as increased implementation of BEN guidelines may allow for broader use of clozapine.

2024-01-22·Medicina (Kaunas, Lithuania)

Assessment of Retinal Microangiopathy in Patients with Balkan Endemic Nephropathy Using Optical Coherence Tomography Angiography-A Pilot Study.

Article

作者: Jasmina Djordjevic-Jocic ; Jovana Cukuranovic Kokoris ; Branka Mitic ; Dragan Bogdanovic ; Marija Trenkic ; Nevena Zlatanovic ; Hristina Jocic ; Rade Cukuranovic

Background and Objectives: It is well known that alterations in microvascular structure and function contribute to the development of ocular, renal, and cardiovascular diseases. Accordingly, the presence of fundus vascular changes in patients suffering from chronic kidney disease (CKD) and Balkan endemic nephropathy (BEN) may provide information of prognostic value regarding the progression of renal disease. This study aimed to examine the associations between clinical characteristics and retinal optical coherence tomography angiography (OCTA) parameters in patients with BEN and compare them with those in CKD. Materials and Methods: This pilot study, conducted from March 2021 to April 2022, included 63 patients who were divided into two groups: the first group consisted of 29 patients suffering from BEN, and the second was a control group of 34 patients with CKD. Demographic, laboratory, clinical, and medication data were noted for all the patients included in this study. Each eye underwent OCT angiography, and the results were interpreted in accordance with the practical guide for the interpretation of OCTA findings. Results: Statistically significantly higher levels of total serum protein and triglycerides were recorded in the BEN group than in the CKD group, while the level of HDL cholesterol was lower. Based on the performed urinalysis, statistically significantly higher values of total protein and creatinine were detected in patients with CKD compared to the BEN group. It was demonstrated that the OCTA vascular plexus density of certain parts of the retina was in significant association with systolic and diastolic blood pressure, creatinine clearance, urinary creatinine, total cholesterol, diabetes mellitus type 2, age, body mass index, total serum and urinary protein, sCRP, and diuretic and antihypertensive treatment. Conclusions: In comparison with CKD, BEN leads to more significant disturbances in retinal vasculature density.

项与巴尔干肾病相关的新闻（医药）

2023-01-23

·NS Medical Devices

Universal DX reports effective detection of CRC using combined technique

The study showed that early-stage (I-II) CRCs detection using the methylation and fragmentation features of cancer-related cfDNA regions in combination with a machine-learning algorithm showed 92% sensitivity at 94% specificity Universal DX will present the study results at ASCO Gastrointestinal Cancers Symposium. (Credit: Akram Huseyn on Unsplash) Universal Diagnostics (Universal DX) announced that the combination of cell-free DNA (cfDNA) methylation, fragmentation, and machine learning to detect early-stage colorectal cancer (CRC) was found to be effective as per an international, observational cohort study. The research from the US-based bioinformatics and multi-omics firm showed that early-stage (I-II) CRCs detection using the methylation and fragmentation features of cancer-related cfDNA regions in combination with a machine-learning algorithm showed 92% sensitivity at 94% specificity. The observational cohort study evaluated a patient sample set gathered from the US, Spain, Germany, and Ukraine. Its results will be presented at the ASCO Gastrointestinal Cancers Symposium. As per the results, the prediction model correctly classified 92% of CRC patients. The sensitivity per cancer stage varied from 91% for stage I, 92% for stage II, 91% for stage III, and 93% for stage IV. The multi-omics firm said that the specificity of the model was 94%, and it correctly identified 97% non-advanced adenoma (NAA), 93% benign colonoscopy findings of diverticulosis/diverticulitis, haemorrhoids, hyperplastic/inflammatory polyps (BEN), and 94% colonoscopy negative (cNEG). Universal DX COO Christian Hense said: “This study further validates and reinforces the work we are doing to develop tests that detect cancer in its earliest stages. “With a completely new sample set, we have again demonstrated highly-accurate early-stage CRC detection, further verifying the robustness of our technology and use of biomarkers to find traces of cancer in a person’s blood. “At Universal DX, we believe early detection is one of the most powerful tools for improving survival rates, and are encouraged to see these promising results once again.” Previously, the US-based firm demonstrated that non-invasive blood testing can be employed to detect CRC and pre-cancerous advanced adenomas (AA). The testing is done via the analysis of cell-free circulating tumour DNA (ctDNA) methylation, fragmentation, and microbiome patterns with single targeted sequencing analysis, combined with advanced computational biology and machine learning algorithms. Last year, the company expanded early-stage colorectal cancer detection to prognostics and stratification in order to improve outcomes and survival rates.

临床结果临床研究